Wedbush Issues Pessimistic Forecast for Arcus Biosciences (NYSE:RCUS) Stock Price

Posted by George Bondi on Nov 5th, 2026

Arcus Biosciences (NYSE:RCUS – Get Free Report) had its price target cut by analysts at Wedbush from $49.00 to $45.00 in a research note issued to investors on Thursday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Wedbush‘s target price suggests a potential upside of 132.87% from the stock’s current price.

A number of other analysts have also weighed in on the stock. Morgan Stanley set a $23.00 price target on shares of Arcus Biosciences in a report on Monday, August 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcus Biosciences in a report on Friday, September 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcus Biosciences in a report on Thursday, October 15th. Wells Fargo & Company increased their price objective on Arcus Biosciences from $23.00 to $26.00 and gave the company an “equal weight” rating in a research report on Thursday, August 6th. Finally, Truist Financial lifted their target price on Arcus Biosciences from $40.00 to $41.00 and gave the company a “buy” rating in a research note on Wednesday, October 21st. Twelve equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $39.27.

Get Our Latest Analysis on Arcus Biosciences

Arcus Biosciences Stock Up 2.2%

Shares of NYSE:RCUS opened at $19.32 on Thursday. Arcus Biosciences has a 12 month low of $17.43 and a 12 month high of $31.74. The company’s 50-day moving average price is $24.26 and its two-hundred day moving average price is $24.58. The company has a quick ratio of 3.82, a current ratio of 3.82 and a debt-to-equity ratio of 0.22. The firm has a market cap of $2.46 billion, a P/E ratio of -4.95 and a beta of 1.04.

Arcus Biosciences (NYSE:RCUS – Get Free Report) last announced its earnings results on Wednesday, November 4th. The company reported ($1.00) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.11). Arcus Biosciences had a negative return on equity of 89.54% and a negative net margin of 393.16%. The company had revenue of $9.00 million during the quarter, compared to the consensus estimate of $7.58 million. During the same period in the prior year, the firm posted ($1.27) earnings per share. The company’s revenue was down 65.4% on a year-over-year basis. As a group, research analysts forecast that Arcus Biosciences will post -3.55 EPS for the current fiscal year.

Insider Activity

In other news, CAO Alexander Azoy sold 2,827 shares of Arcus Biosciences stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $30.00, for a total transaction of $84,810.00. Following the completion of the sale, the chief accounting officer owned 39,581 shares in the company, valued at $1,187,430. The trade was a 6.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Arcus Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. bought a new position in Arcus Biosciences in the second quarter valued at approximately $506,113,000. Parkman Healthcare Partners LLC acquired a new stake in Arcus Biosciences during the 2nd quarter worth $28,341,000. Bank of America Corp DE acquired a new stake in Arcus Biosciences during the 2nd quarter worth $25,759,000. Bank of New York Mellon Corp bought a new stake in shares of Arcus Biosciences during the 2nd quarter valued at $16,741,000. Finally, Renaissance Technologies LLC raised its position in shares of Arcus Biosciences by 1,198.8% during the 1st quarter. Renaissance Technologies LLC now owns 424,700 shares of the company’s stock valued at $9,174,000 after acquiring an additional 392,000 shares during the last quarter. 92.89% of the stock is owned by institutional investors.

Key Arcus Biosciences News

Here are the key news stories impacting Arcus Biosciences this week:

Positive Sentiment: Analysts’ average price target is reported at $39.64, well above the stock’s recent trading level. Price targets are estimates, not guarantees. Article: Arcus Biosciences Stock Has Average Target Price of $39.64 According to Analysts
Neutral Sentiment: Arcus provided a pipeline update alongside its results. The available report excerpt mentions October HIF-2 data but does not provide enough detail to assess the update’s potential impact. Article: Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline Update
Negative Sentiment: Third-quarter loss was $1.00 per share, missing the cited consensus estimate of a $0.89 loss. Revenue was $9 million—above one reported estimate of $7.58 million, but down 65.4% from a year earlier. The loss did narrow from $1.27 per share in the prior-year quarter. Article: Arcus Biosciences Reports Q3 Loss

Arcus Biosciences Company Profile

(Get Free Report)

Arcus Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. The company uses its research platform to discover and advance medicines designed to target immune suppression and other biological mechanisms involved in tumor growth.

Arcus’s oncology pipeline has included antibody-based and small-molecule therapies aimed at targets such as TIGIT, PD-1, CD73, and the adenosine A2A and A2B receptors. Its key development programs have included domvanalimab, zimberelimab, quemliclustat, and etrumadenant, which have been evaluated in clinical studies across several cancer types, including lung, gastrointestinal, and colorectal cancers.

Founded in 2015 and headquartered in Hayward, California, Arcus conducts research and clinical-development activities intended to support potential commercialization in international markets.